Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer

Runsen Jin; Chengming Liu; Sufei Zheng; Xinfeng Wang; Xiaoli Feng; Hecheng Li; Nan Sun; Jie He

doi:10.20892/j.issn.2095-3941.2020.0121

Article Information

vol. 17 no. 3 768-781

DOI

https://doi.org/10.20892/j.issn.2095-3941.2020.0121

Published By

Cancer Biology & Medicine

History

Received March 26, 2020
Accepted June 28, 2020
Published online August 15, 2020.

Copyright: © 2020, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

Runsen Jin1,2,*,
Chengming Liu1,*,
Sufei Zheng1,
Xinfeng Wang1,
Xiaoli Feng3,
Hecheng Li2,
Nan Sun1 ⇑ and
Jie He1 ⇑

¹Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
²Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
³Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China